RPG Life Sciences Limited Asset Resilience Ratio
RPG Life Sciences Limited asset resilience ratio. RPG Life Sciences Limited (RPGLIFE) has an Asset Resilience Ratio of 10.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of RPG Life Sciences Limited to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of RPG Life Sciences Limited (2017–2026)
Asset resilience ratio of RPG Life Sciences Limited from 2017 to 2026. This chart shows how RPG Life Sciences Limited's Asset Resilience Ratio has changed over time. Read RPG Life Sciences Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down RPG Life Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RPG Life Sciences Limited (RPGLIFE) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs839.00 Million | 10.58% |
| Total Liquid Assets | Rs839.00 Million | 10.58% |
Asset Resilience Insights
- Moderate Liquidity: RPG Life Sciences Limited has 10.58% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
RPG Life Sciences Limited Industry Peers by Asset Resilience Ratio
Compare RPG Life Sciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
RPG Life Sciences Limited Asset Resilience Ratio by Year (2017–2026)
RPG Life Sciences Limited asset resilience ratio by year from 2017 to 2026. The table below shows the annual Asset Resilience Ratio data for RPG Life Sciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 15.62% | Rs1.24 Billion ≈ $13.40 Million |
Rs7.93 Billion ≈ $85.78 Million |
-24.19pp |
| 2025-03-31 | 39.81% | Rs2.62 Billion ≈ $28.32 Million |
Rs6.58 Billion ≈ $71.14 Million |
+15.80pp |
| 2024-03-31 | 24.01% | Rs1.23 Billion ≈ $13.32 Million |
Rs5.13 Billion ≈ $55.46 Million |
-5.13pp |
| 2023-03-31 | 29.14% | Rs1.22 Billion ≈ $13.22 Million |
Rs4.19 Billion ≈ $45.35 Million |
+25.41pp |
| 2022-03-31 | 3.73% | Rs128.60 Million ≈ $1.39 Million |
Rs3.45 Billion ≈ $37.27 Million |
+3.23pp |
| 2021-03-31 | 0.50% | Rs15.30 Million ≈ $165.46K |
Rs3.03 Billion ≈ $32.81 Million |
+0.46pp |
| 2020-03-31 | 0.04% | Rs1.20 Million ≈ $12.98K |
Rs2.67 Billion ≈ $28.85 Million |
0.00pp |
| 2019-03-31 | 0.05% | Rs1.20 Million ≈ $12.98K |
Rs2.51 Billion ≈ $27.17 Million |
-0.24pp |
| 2018-03-31 | 0.28% | Rs8.30 Million ≈ $89.76K |
Rs2.91 Billion ≈ $31.50 Million |
+0.08pp |
| 2017-03-31 | 0.20% | Rs5.00 Million ≈ $54.07K |
Rs2.46 Billion ≈ $26.63 Million |
-- |
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. … Read more